Kymera Therapeutics

Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting

Data demonstrate KT-413’s potential as a monotherapy and in combination with rituximab or BTK inhibitors, with potent antitumor activity in multiple xenograft models of MYD88 MT DLBCL WATERTOWN, Mass., June 09, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc.